Binimetinib usual dose is 45 mg twice daily. Binimetinib is used in combination with Encorafenib for metastatic melanoma and non-small cell lung cancer. Please consult your physician for specific dosing.
Binimetinib Dosing Guide
1. Indications
(1) Binimetinib is indicated in combination with Encorafenib for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.
(2) Binimetinib is indicated in combination with Encorafenib for adult patients with metastatic non-small cell lung cancer with BRAF V600E mutation.
2. Recommended Adult Dosage
Unresectable or metastatic melanoma and metastatic non-small cell lung cancer: 45 mg orally twice daily (every 12 hours) in combination with Encorafenib until disease progression or unacceptable toxicity.
3. Administration
Binimetinib may be taken with or without food.
4. Missed Dose
If the next scheduled dose is more than 6 hours away, take the missed dose as soon as possible. If the next scheduled dose is less than 6 hours away, skip the missed dose and resume the regular dosing schedule.
5. Vomiting
If vomiting occurs after taking a dose, do not take an additional dose; resume the next dose as scheduled.
Dose Adjustments in Special Populations
1. Renal Impairment
No dose adjustment is required.
2. Hepatic Impairment
Mild hepatic impairment (total bilirubin >1 and ≤1.5× upper limit of normal (ULN) with any AST ≤ULN; or total bilirubin ≤ULN with AST >ULN): No dose adjustment is required.
Moderate hepatic impairment (total bilirubin >1.5 and ≤3× ULN with any AST) or severe hepatic impairment (total bilirubin >3× ULN with any AST): Recommended dose is 30 mg orally twice daily.
General Dose Modification Principles
If Encorafenib is permanently discontinued, Binimetinib should also be discontinued.
Dose Adjustments for Adverse Reactions
1. First dose reduction: 30 mg twice daily (every 12 hours).
2. Subsequent modification: If 30 mg twice daily cannot be tolerated, permanently discontinue Binimetinib.
